![VA HSR&D Podcasts artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts113/v4/7a/83/fe/7a83fe9c-44d9-976c-95cc-938b261f0454/mza_7905553282644168621.jpg/100x100bb.jpg)
Evaluating Prophylactic Anticoagulant Therapy Effectiveness for Treating COVID-19
VA HSR&D Podcasts
English - September 17, 2021 09:15 - 17 minutes - 1 KB - ★★★★★ - 2 ratingsScience Health & Fitness Medicine veterans health services research department affairs researchers investigators economics hsr Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
In this episode, Dr. Christopher Rentsch, of the London School of Hygiene and Tropical Medicine and Yale University, talks about a <a href="https://www.bmj.com/content/372/bmj.n311" target="_blank">large-scale evaluation of the effectiveness of prophylactic anticoagulant therapy</a> for the treatment of COVID-19.<br><br>
Since the recording of this podcast, the largest trial to date, ACTIV-4, has found that initiating therapeutic anticoagulation compared to prophylactic anticoagulation provided additional benefit among patients hospitalized with COVID-19. Both Dr. Rentsch’s study and the ACTIV-4 study found benefit in <a href="https://www.nejm.org/doi/10.1056/NEJMoa2105911" target="_blank">noncritically ill</a> patients yet not in <a href="https://www.nejm.org/doi/10.1056/NEJMoa2103417">critically ill</a> patients.